Orforglipron≥99% CAS No: 2212020-52-3
Orforglipron≥99% CAS No: 2212020-52-3
Orforglipron,Orforglipron reagent,LY3502970,High purity Orforglipron,GLP-1 research compound
Product Name: Orforglipron API Powder
Product purity:≥99%
CAS No：2212020-52-3
Send Inquiry
Description
Oral Small-Molecule GLP-1R Agonist
Orforglipron (LY3502970)
High-Purity Research Reagent for Metabolic Disease & Target Validation Studies
ATTENTION:
This product is a chemically synthesized compound strictly for Laboratory Research & Development (R&D). It is NOT for human or clinical use. Shaanxi Sunrise Pharmaceutical Co., Ltd. provides this material exclusively to qualified research institutions.
Scientific Product Description
Orforglipron (LY3502970) is a potent, selective, and non-peptide small-molecule agonist of the Glucagon-Like Peptide-1 Receptor (GLP-1R). As a synthetic crystalline powder, it represents the next generation of metabolic research tools.
Unlike traditional peptide agonists (such as Semaglutide) that require subcutaneous injection or specialized absorption enhancers for oral delivery, Orforglipron’s small-molecule architecture inherently allows for high oral bioavailability. This makes it an invaluable reference material for labs studying oral delivery mechanisms, GPCR signaling, and metabolic rate regulation.
Advanced Mechanism of Action
Biochemical GPCR Activation
In academic research models, Orforglipron interacts with the GLP-1 receptor via a distinct mechanism:
Selective Binding: It targets the orthosteric binding pocket of the GLP-1 receptor with high affinity, mirroring the effects of endogenous GLP-1.
cAMP Cascade: Activation triggers the Gαs protein pathway, leading to increased intracellular cyclic AMP (cAMP) levels in experimental cell lines.
Beta-Arrestin Recruitment: Research studies utilize Orforglipron to evaluate biased signaling profiles compared to native peptides.
Structural Advantages in Research
The transition from peptide to small-molecule agonists offers several parameters for comparative laboratory study:
| Parameter | Orforglipron (Small Molecule) | Peptide Agonists (e.g. Semaglutide) |
|---|---|---|
| Chemical Stability | High (Resistant to Proteases) | Low (Vulnerable to Peptidases) |
| Molecular Weight | ~764.8 Da (Small Molecule) | ~4113.6 Da (Large Peptide) |
| Absorption Model | Passive Diffusion / Transporters | Specialized Endocytosis |
| Research Flexibility | Ideal for Oral Formulation R&D | Limited to Injectable/SNAC models |
Core Research Applications
Metabolic Pathway Mapping: Investigating the effects of non-peptide agonists on insulin secretion mechanisms in in vitro pancreatic islet models.
GPCR Structural Biology: Utilizing Orforglipron for cryo-EM studies of the GLP-1 receptor in active conformations.
Weight Regulation Studies: Experimental research on central nervous system (CNS) GLP-1R signaling and satiety in animal models (Ethical approval required).
Quality Assurance by Shaanxi Sunrise
Our Orforglipron is manufactured under ISO 9001:2015 guidelines to ensure the highest reproducibility for your experiments:
COA Provided: Every batch includes an electronic Certificate of Analysis (COA).
Purity Verification: Double-verified by HPLC and LC-MS.
Contaminant Control: Rigorous testing for residual solvents and heavy metals.